Great progress! We've reached 1/3 enrollment in the COLFIB trial: 167/500 afib patients! 🎉 This trial, randomizing between placebo & colchicine, aims to prove colchicine's cardioprotective capabilities. Stay tuned for results!#COLFIB#Arrhythmia#Colchicine@CTCPR_@TorBiering
🫀my first PhD article - our #CARISMA sub study on the risk of #arrhythmias after #ACS according to mode of #revascularization - has made it to the new 2025 ACC/AHA guideline for the management of #ACS 👇
Our most recent paper by the brilliant Daniel Modin on the impact of Influenza in patients with HF just published in @JACCJournals 👇
@CTCPR_@koebenhavns_uni
DANFLU-2 is yet again breaking all records on pragmatic trial conduct. We randomized more than 50000 Danes in just the first week of this year’s inclusion.
In total 340000 Danes will be randomized over 3 seasons.
The results will be out next summer!
https://t.co/TgGRR8w3vG
Simultaneously publication by Jacob Christensen from @CTCPR_ at #ESCCongress
Relative Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults with Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial 👇
Today we finalized the inclusion of DECODE-CKD, a mechanistic RCT to study the cardioprotective effects of SGLT2i in people with chronic kidney disease.
@TorBiering@CTCPR_
1/3
Congratulations 👏 to @katjabartholdy and the rest of the amazing @CTCPR_ team for finalizing recruitment of our DECODE-CKD trial. Results will be ready in 6 months. Please read more about the trial in the design paper. See link below 👇
https://t.co/cEoyf93PkX
New study: prevalence & implications of HF stages in patients with CKD 🚨
prospective cohort of 825 CKD pts
HF stages A to D ⬆️ with ⬆️ CKD stages
HF may be underdx in CKD: 8.8% had diagnosis but 15.3% had HF stage C/D!!🫀
@TorBiering@JACCJournals
https://t.co/zOPuOFBAOl
Awesome to present the main results of the NUDGE-FLU-CHRONIC trial as LBCT yesterday at #ESCMIDGlobal!
Our nudges increased flu vacc uptake from 28% to 40% in 18-64 yos with chronic diseases in Denmark, corresponding to 25,000 additional vaccinees!
Our most recent analysis from the NUDGE-FLU trial assessing the effect of NUDGES to increase flu vaccine uptake amongst DM patients just published in @JAMA_current Open. Analysis lead by the brilliant @matslassen 👏
Today we reached yet another important milestone in the DANFLU-2 trial. We randomized more than 150.000 participants in just 3 weeks. The DANFLU-2 trial is revolutionizing how to use nationwide registries to execute large scale outcome RCT’s @CIRL_DK
https://t.co/gaPNswmVcj…
Today we reached an important milestone for DANFLU-2. We randomized more than 100.000 in just 2 weeks. I believe this is the largest number of randomized individuals in any RCT using individual randomization. What a remarkable teamwork at @CIRL_DK
More: https://t.co/kJPJ5846Ql
Ready for a case report?
In this @CircHF article the authors @ersboell_mads @FinnGustafsson et al. present a rare case of a 59-year-old female w/ high output #HF caused by a renal clear cell carcinoma 🫀😮💨 one to remember in the diagnostic work-around in this patient group‼️